GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioVie Inc (NAS:BIVI) » Definitions » Shiller PE Ratio

BioVie (BioVie) Shiller PE Ratio : (As of May. 21, 2024)


View and export this data going back to 2014. Start your Free Trial

What is BioVie Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


BioVie Shiller PE Ratio Historical Data

The historical data trend for BioVie's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioVie Shiller PE Ratio Chart

BioVie Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

BioVie Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of BioVie's Shiller PE Ratio

For the Biotechnology subindustry, BioVie's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioVie's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioVie's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where BioVie's Shiller PE Ratio falls into.



BioVie Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

BioVie's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, BioVie's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.2/131.7762*131.7762
=-0.200

Current CPI (Mar. 2024) = 131.7762.

BioVie Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 -0.249 100.560 -0.326
201409 -0.084 100.428 -0.110
201412 -0.101 99.070 -0.134
201503 -0.070 99.621 -0.093
201506 -0.079 100.684 -0.103
201509 -0.078 100.392 -0.102
201512 -0.071 99.792 -0.094
201603 -0.083 100.470 -0.109
201606 -0.387 101.688 -0.502
201609 -0.504 101.861 -0.652
201612 -0.511 101.863 -0.661
201703 -0.244 102.862 -0.313
201706 0.000 103.349 0.000
201709 -1.250 104.136 -1.582
201712 -1.250 104.011 -1.584
201803 -1.250 105.290 -1.564
201806 -1.250 106.317 -1.549
201809 -0.197 106.507 -0.244
201812 -0.200 105.998 -0.249
201903 -0.340 107.251 -0.418
201906 -0.250 108.070 -0.305
201909 -5.060 108.329 -6.155
201912 1.290 108.420 1.568
202003 -0.070 108.902 -0.085
202006 -3.830 108.767 -4.640
202009 -7.750 109.815 -9.300
202012 -0.220 109.897 -0.264
202103 -0.220 111.754 -0.259
202106 -10.180 114.631 -11.703
202109 -0.230 115.734 -0.262
202112 -0.220 117.630 -0.246
202203 -0.280 121.301 -0.304
202206 -0.330 125.017 -0.348
202209 -0.380 125.227 -0.400
202212 -0.500 125.222 -0.526
202303 -0.430 127.348 -0.445
202306 -0.230 128.729 -0.235
202309 -0.290 129.860 -0.294
202312 -0.220 129.419 -0.224
202403 -0.200 131.776 -0.200

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


BioVie  (NAS:BIVI) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


BioVie Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of BioVie's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


BioVie (BioVie) Business Description

Traded in Other Exchanges
N/A
Address
680 W Nye Lane, Suite 204, Carson, NV, USA, 89703
BioVie Inc is a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The Company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.
Executives
Steve Gorlin director 150 GULF SHORE DRIVE, UNIT 601, DESTIN FL 32541
Cuong V Do director C/O BIOVIE, 2120 COLORADO AVENUE, SUITE 230, SANTA MONICA CA 90404
Richard J Berman director 305 COLLEGE ROAD EAST, PRINCETON NJ 08540
James Paul Lang director C/O BIOVIE, 2120 COLORADO AVENUE, SUITE 230, SANTA MONICA CA 90404
Michael Edward Sherman director C/O BIOVIE, 2120 COLORADO AVENUE, SUITE 230, SANTA MONICA CA 90404
Robert J Hariri director 341 MENDHAM ROAD, BERNARDSVILLE NJ 07924
Joanne Wendy Kim officer: Chief Financial Officer C/O BIOVIE, INC, 2120 COLORADO AVENUE, SUITE 230, SANTA MONICA CA 90404
Joseph M Palumbo other: Chief Medical Officer 616 BROOKSIDE AVENUE, SAINT DAVIDS PA 19087
Jonathan M Adams officer: EVP Liver Cirrhosis Programs 100 CUMMINGS CENTER 247C, BEVERLY MA 01915
Penelope Markham officer: EVP Liver Cirrhosis R&D C/O BIOVIE, INC, 2120 COLORADO AVENUE, SUITE 230, SANTA MONICA CA 90404
Christopher Reading officer: EVP Neuroscience R&D C/O HOLLIS-EDEN PHARMACEUTICALS, 4435 EASTGATE MALL STE.400, SAN DIEGO CA 92121
Clarence N. Ahlem officer: EVP of Product Development 5305 RENAISSANCE AVE., SAN DIEGO CA 92122
Mina Sooch director 17199 N. LAUREL PARK DRIVE, SUITE 401, LIVONIA MI 48152
Sigmund Rogich director C/O BIOVIE, 2120 COLORADO AVENUE, SUITE 230, SANTA MONICA CA 90404
Patrick D Yeramian officer: Chief Medical Officer 1815 PARKSIDE CIRCLE SOUTH, BOCA RATON FL 33486

BioVie (BioVie) Headlines

From GuruFocus